Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed Antibody TherapyRajat Bannerji, Carrie Brownstein, Susan O’Brien et al.|Blood|2016Cited by 19
<i>Ameli-01: Phase I, Open Label Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART123 (allogeneic engineered T-cells expressing anti-CD123 chimeric antigen receptor), Administered in Patients with Relapsed/Refractory Acute Myeloid Leukemia</i>Gail J. Roboz, Naveen Pemmaraju, Daniel J. DeAngelo et al.|Blood|2020Cited by 11